Abstract:One of the major obstacles in human epidermal growth factor receptor 2 (HER2)-specific trastuzumab antibody immunotherapy of HER2-positive breast cancer is the development of trastuzumab resistance, warranting the search for other therapeutic strategies. Using mouse models, we previously demonstrated that ovalbumin (OVA)-specific dendritic cell (DC)-released exosome (EXOOVA)-targeted CD4+ T cell-based (OVA-TEXO) vaccine stimulates efficient cytotoxic T lymphocyte (CTL) responses via exosomal peptide/major histocompatibility complex (pMHC)-I, exosomal CD80 and endogenous IL-2 signaling; and long-term CTL memory by means of via endogenous CD40L signaling. In this study, using two-photon microscopy, we provide the first visual evidence on targeting OVA-TEXO to cognate CD8+ T cells in vivo via exosomal pMHC-I complex. We prepared HER2/neu-specific Neu-TEXO and HER2-TEXO vaccines using adenoviral vector (AdVneu and AdVHER2)-transfected DC (DCneu and DCHER2)-released EXOs (EXOneu and EXOHER2), and assessed their stimulatory effects on HER2/neu-specific CTL responses and antitumor immunity. We demonstrate that Neu-TEXO vaccine is capable of stimulating efficient neu-specific CTL responses, leading to protective immunity against neu-expressing Tg1-1 breast cancer in all 6/6 transgenic (Tg) FVBneuN mice with neu-specific self-immune tolerance. We also demonstrate that HER2-TEXO vaccine is capable of inducing HER2-specific CTL responses and protective immunity against transgene HLA-A2+HER2+ BL6-10A2/HER2 B16 melanoma in 2/8 double Tg HLA-A2/HER2 mice with HER2-specific self-immune tolerance. The remaining 6/8 mice had significantly prolonged survival. Furthermore, we demonstrate that HER2-TEXO vaccine stimulates responses of CD8+ T cells capable of not only inducing killing activity to HLA-A2+HER2+ BL6-10A2/HER2 melanoma and trastuzumab-resistant BT474A2 breast cancer cells in vitro but also eradicating 6-day palpable HER2+ BT474A2 breast cancer (3–4 mm in diameter) in athymic nude mice. Therefore, the novel T cell-based HER2-TEXO vaccine may provide a new therapeutic alternative for women with HER2+ breast cancer, especially for trastuzumab-resistant HER2+ breast cancer patients.

Novel Exosome-Targeted Cd4(+) T Cell Vaccine Counteracting Cd4(+)25(+) Regulatory T Cell-Mediated Immune Suppression and Stimulating Efficient Central Memory Cd8(+) Ctl Responses

Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.

More efficient induction of antitumor T cell immunity by exosomes from CD40L gene-modified lung tumor cells.

CD4 + T cell-released exosomes inhibit CD8 + cytotoxic T-lymphocyte responses and antitumor immunity

Dendritic Cell-Derived Exosomes Stimulate Stronger Cd8(+) Ctl Responses and Antitumor Immunity Than Tumor Cell-Derived Exosomes

Novel Exosome-Targeted T-Cell-Based Vaccine Counteracts T-Cell Anergy and Converts Ctl Exhaustion in Chronic Infection Via Cd40l Signaling Through the Mtorc1 Pathway

In vivo anti-tumor effect of tumor cell-derived exosomes combined with BCG

Exosomal Pmhc-I Complex Targets T Cell-Based Vaccine to Directly Stimulate CTL Responses Leading to Antitumor Immunity in Transgenic FVBneuN and HLA-A2/HER2 Mice and Eradicating Trastuzumab-Resistant Tumor in Athymic Nude Mice

Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8 + CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells

Therapeutic exosomal vaccine for enhanced cancer immunotherapy by mediating tumor microenvironment

CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes.

Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity.

Cd8(+) Cytotoxic T-Apc Stimulate Central Memoiry Cd8(+) T Cell Responses Via Acquired Peptide-Mhc Class I Complexes And Cd80 Costimulation, And Rl-2 Secretion

Immune Adjuvant Targeting Micelles Allow Efficient Dendritic Cell Migration to Lymph Nodes for Enhanced Cellular Immunity.

Tumor Cell-Derived Exosome-Targeted Dendritic Cells Stimulate Stronger CD8+ CTL Responses and Antitumor Immunities

A Novel Costimulatory Molecule Gene-Modified Leukemia Cell-Derived Exosome-Targeted CD4+ T Cell Vaccine Efficiently Enhances Anti-Leukemia Immunity

PD-L1 Antibodies-Armed Exosomal Vaccine for Enhanced Cancer Immunotherapy by Simultaneously in Situ Activating T Cells and Blocking PD-1/PD-L1 Axis

Tumor Cell-associated Exosomes Robustly Elicit Anti-tumor Immune Responses through Modulating Dendritic Cell Vaccines in Lung Tumor

Enhancing immune responses of ESC-based TAA cancer vaccines with a novel OMV delivery system

Increasing vaccine potency through exosome antigen targeting

Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells.